The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

elementscience.com

Founded Year

2011

Stage

Series C | Alive

Total Raised

$192.6M

Last Raised

$145.6M | 2 yrs ago

About Element Science

Element Science focuses on solutions at the intersection of life-saving therapies, wearable devices, and patient-centric design. The company develops a cost-effective wearable therapeutic device that aims to re-define the treatment for temporary periods of elevated sudden cardiac death risk.

Element Science Headquarter Location

200 Kansas Street Suite 210

San Francisco, California, 94103,

United States

415-872-6500

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Element Science

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Element Science in 3 CB Insights research briefs, most recently on Dec 8, 2021.

Expert Collections containing Element Science

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Element Science is included in 8 Expert Collections, including Wearable Computing.

W

Wearable Computing

404 items

Wearable computing is broadly defined as companies developing devices worn or placed on the body that are equipped with technology, which can range from wearable medical devices to AR/VR headsets to GPS pet collars.

M

Medical Devices

8,684 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.

S

Smart Home & Consumer Electronics

1,164 items

This Collection includes companies developing smart home devices, wearables, home electronics, and other consumer electronics.

D

Digital Health 150

150 items

The winners of the second annual CB Insights Digital Health 150.

D

Digital Health

13,075 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)

T

Telehealth

2,833 items

Companies developing, offering, or using electronic and telecommunication technologies to facilitate the delivery of health & wellness services from a distance. *Columns updated as regularly as possible; priority given to companies with the most and/or most recent funding.

Element Science Patents

Element Science has filed 7 patents.

The 3 most popular patent topics include:

  • Cardiac electrophysiology
  • Implants (medicine)
  • Cardiac arrhythmia
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/10/2019

2/22/2022

Cardiac electrophysiology, Cardiac arrhythmia, Emergency medical responders, Implants (medicine), Capacitors

Grant

Application Date

10/10/2019

Grant Date

2/22/2022

Title

Related Topics

Cardiac electrophysiology, Cardiac arrhythmia, Emergency medical responders, Implants (medicine), Capacitors

Status

Grant

Latest Element Science News

Element Science Announces First Patient Save with Jewel Patch Wearable Cardioverter Defibrillator (P-WCD)

Aug 2, 2022

August 02, 2022 11:00 AM Eastern Daylight Time SAN FRANCISCO--( BUSINESS WIRE )-- Element Science , an innovative health technology company pioneering a next-generation digital wearable platform for high-risk cardiovascular patients transitioning from hospital to home, today announced the first patient save from a successful defibrillation early in the enrollment of the Investigational Device Exception (IDE) Study of its Jewel Patch Wearable Cardioverter Defibrillator (P-WCD). The Jewel P-WCD is a low-profile wearable defibrillator designed to detect and treat life-threatening arrhythmias in patients with a high temporary risk for Sudden Cardiac Arrest (SCA), a condition that affects more than 500,000 patients in the US annually. Jewel P-WCD Patient Save As the first real-world demonstration of the Jewel P-WCD’s therapeutic benefit, a patient enrolled in the study experienced SCA at home due to a life-threatening arrhythmia that was both appropriately detected and treated by the Jewel P-WCD the patient was wearing. This patient experienced the life-threatening arrhythmia in the first week after returning home to a rural area where emergency response teams are not immediately available. In this instance, the Jewel successfully saved the patient, restoring a normal rhythm with one defibrillation shock and allowing time for first responders to arrive. The patient was transported to the hospital for further care and has since received an implantable defibrillator and is recovering well. “At Element Science, our goal has always been to redefine the paradigm of care as patients return home after being treated for significant cardiovascular events such as a heart attack or a diagnosis of heart failure,” said Uday N. Kumar, MD, Founder, President and CEO. “Our entire team is grateful to have been able to meaningfully help this patient. The continuous protection afforded by the Jewel P-WCD that helped ensure the patient was wearing the device when needed is precisely the situation for which this device was developed.” He added, “As a cardiac electrophysiologist, I know that during the first weeks and months after patients have suffered an acute cardiovascular event, they are at high risk of experiencing a life-threatening arrhythmia as they recover. We are delighted to have partnered with leading physicians across the country to conduct this study and this first patient save early in the IDE study clearly demonstrates the benefits of this important technology.” Jewel P-WCD IDE Study The Principal Investigators for the Jewel IDE Study were selected for their diverse practices as well as their personal backgrounds and locations to ensure that a wide range of eligible patients, representing significant racial, ethnic and gender diversity, are represented in this landmark trial. They are: John Hummel, MD, The Ohio State University, Director, Electrophysiology Section; Javed Butler, MD, University of Mississippi, Patrick H. Lehan Chair in Cardiovascular Research; and Roxana Mehran, MD, Mount Sinai, Director of Interventional Cardiovascular Research and Clinical Trials. Dr. Butler commented, “Participating in a study that is evaluating the real-world potential of a personalized wearable patch for high-risk cardiovascular patients is very important to hospitals and clinics across the country. Cardiologists in Mississippi treat a broad array of patients for whom there is an enormous unmet need to help them confidently return home following a cardiovascular episode and we welcome the opportunity to include these patients in the study.” “I am honored to work with dedicated cardiologists across the country who share my passion for moving care safely from hospital to home,” said Zubin J. Eapen, MD, MHS, Chief Medical Officer, Element Science. “By designing the Jewel P-WCD to provide continuous life-saving therapy, even during activities like showering when other wearable defibrillators typically cannot be used, we are able to assure physicians that their vulnerable patients are receiving the highest level of protection.” Dr. Robert Harrington, a cardiologist who is currently a Professor and Chair of the Department of Medicine at Stanford University and who is also a long-time member of the Company’s Scientific Advisory Board, stated: "As a clinician, I am acutely aware of the risk patients face when returning home after an acute cardiac event. The Jewel P-WCD coming to fruition is an important advancement to help protect patients in the case of out-of-hospital SCA. I am looking forward to continued progress in this ongoing clinical trial." The study is designed to evaluate the safety and effectiveness of the Jewel P-WCD and is enrolling up to 370 patients across the U.S. who are at high risk for life threatening cardiac arrhythmias. The Jewel P-WCD will be used in the trial to monitor heart rhythms and treat subjects with defibrillation as needed. The trial is expected to be completed in 2023. *The Jewel P-WCD is an investigational device and limited by U.S. law to investigational use only. It is not available for sale. About Element Science, Inc. Element Science, Inc. is a medical device and digital health company focused on developing solutions at the intersection of clinical-grade wearables, machine learning algorithms, and lifesaving therapies in order to address leading causes of death and hospitalization in patients with heart disease, primarily as they transition from the hospital-to-home. By putting the needs of patients and physicians first, our personalized digital devices, which are designed for function, comfort and ease-of-use, aim to redefine the paradigm of care for these patients. Our first product, a wearable patch defibrillator, is initially targeted at treating the more than 500,000 patients in the U.S. with an elevated temporary risk of potentially experiencing a lethal heart rhythm. Based in San Francisco, our funders include Third Rock Ventures, Google Ventures, Deerfield Management, Qiming Venture Partners USA, Cormorant Asset Management, and Invus Opportunities. For more information please visit www.elementscience.com . Contacts

Element Science Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Element Science Rank

  • When was Element Science founded?

    Element Science was founded in 2011.

  • Where is Element Science's headquarters?

    Element Science's headquarters is located at 200 Kansas Street, San Francisco.

  • What is Element Science's latest funding round?

    Element Science's latest funding round is Series C.

  • How much did Element Science raise?

    Element Science raised a total of $192.6M.

  • Who are the investors of Element Science?

    Investors of Element Science include Google Ventures, Third Rock Ventures, Qiming Venture Partners, Deerfield Management, Invus Group and 3 more.

  • Who are Element Science's competitors?

    Competitors of Element Science include Biofourmis, EarLens, Cardiac Insight, Eko, VitalConnect, Hillrom Holdings, Babyscripts, Implandata Ophthalmic Products, Intelligent Implants, Microtech Medical and 31 more.

You May Also Like

VitalConnect Logo
VitalConnect

VitalConnect currently markets the VitalConnect Platform that includes two wearable biosensors combined with mobile and cloud-based software and analytics. HealthPatch MD and VitalPatch biosensors are wireless, adhesive patches that continuously monitor and record single-lead ECG, heart rate, heart rate variability, respiratory rate, skin temperature, posture, step count, and fall detection with clinical accuracy. Through the VitalConnect Platform, care teams receive accurate data and notifications to make health decisions and enable timely interventions.

AliveCor Logo
AliveCor

AliveCor focuses on the creation of FDA-cleared machine learning techniques to enable proactive heart care and is recognized around the world for transforming cardiac care. The FDA-cleared KardiaMobile is a clinically validated mobile EKG solution on the market. It is recommended by cardiologists and used by people worldwide for accurate EKG recordings. KardiaMobile, and KardiaBand, when paired with the Kardia app provide instant analysis for detecting atrial fibrillation (AF) and normal sinus rhythm in an EKG.

MC10 Logo
MC10

MC10 is developing electronic systems through its Conformal Electronics Platform. The platform enhances and enables applications by allowing electronics to occupy spaces and geometries not possible in traditional, rigid form. Backed by a patent portfolio secured both through in-licensing and continued developments at MC10, the company is targeting applications in consumer electronics, medical devices, industrial products, and defense systems.

Bigfoot Biomedical Logo
Bigfoot Biomedical

Bigfoot Biomedical is on a mission to improve the lives of people with insulin-requiring diabetes through the application of smart technology. Bigfoot's approach includes delivering an Internet-of-Things medical device, a cloud-connected system bundled as a monthly subscription service, to a broad population historically challenged by the high upfront costs of traditional insulin delivery hardware.

I
Intelligent Implants

Intelligent Implants is developing electrotherapeutic devices to treat disease and aid recovery in bone and other tissues. The company uses data, engineering, and biologics to bring new, active and connected medical devices to healthcare. These integrated devices facilitate treatment for the patient, as well as, decision making for the healthcare professional.

CeQur Logo
CeQur

CeQur is developing and commercializing advanced yet simple-to-use insulin delivery devices that make it easier for people living with type 2 diabetes to adhere to therapy and stay in control of their disease. The Company's fully optimized device, PaQ, is a three-day, wearable device that provides freedom from multiple daily insulin injections.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.